<DOC>
	<DOCNO>NCT02447315</DOCNO>
	<brief_summary>The purpose study evaluate pharmacodynamic effect oral dos pilocarpine salivary secretion healthy male female subject . In addition , pharmacodynamic effect static pupillometry evaluate well pharmacokinetics safety tolerability oral dos pilocarpine healthy subject .</brief_summary>
	<brief_title>A Study Investigate Effect Oral Doses Pilocarpine Salivary Secretion Static Pupillometry Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Pilocarpine</mesh_term>
	<criteria>Subject body mass index range 18.5 30.0 kg/m2 , inclusive . The subject weigh least 50 kg . [ screen ] Female subject must either : Be nonchildbearing potential : 1 . Postmenopausal ( define least 1 year without menses ) prior screen , 2 . Documented surgically sterile . Or , childbearing potential : 1 . Agree try become pregnant clinical study 28 day final study drug administration , 2 . Must negative serum pregnancy test day 1 , 3 . And , heterosexually active , agree consistently use 2 form highly effective birth control ( least 1 must barrier method ) start screen throughout clinical study period final study drug administration . Highly effective form birth control include : Consistent correct usage establish oral contraception ; Injected implant hormonal method contraception ; Established intrauterine device intrauterine system ; Barrier method contraception : condom occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository . Female subject must agree breastfeed start screen throughout clinical study period , 28 day final study drug administration . Female subject must donate ovum start screen throughout clinical study period , 28 day final study drug administration . Male subject must donate sperm start screen throughout clinical study period , 90 day last study drug administration . Subject agree participate another interventional study participation present clinical study , define signing informed consent form completion last study visit . Female subject pregnant within 6 month prior screen assessment breastfeed within 3 month prior screen . Subject know suspected hypersensitivity pilocarpine component formulation use . Subject clinically significant , uncontrolled cardiorenal disease , uncontrolled asthma , chronic obstructive pulmonary disease , cholelithiasis , urolithiasis , current previous peptic ulcer disease and/or chronic disease risk cholinergic agonist . Subject condition eye could affect intake pilocarpine ( e.g. , acute iritis ) . Subject liver chemistry test ( aspartate aminotransferase [ AST ] , alanine aminotransferase [ ALT ] , alkaline phosphatase [ ALP ] , gamma glutamyl transferase , total bilirubin [ TBL ] ) 1.5 Ã— upper limit normal ( ULN ) . In case , assessment may repeat , day 1 . Subject clinically significant history allergic condition ( include drug allergy , asthma , eczema anaphylactic reaction , exclude untreated , asymptomatic , seasonal allergy time dose ) . Subject history evidence clinically significant cardiovascular , gastrointestinal , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal and/or major disease malignancy . Subject has/had febrile illness symptomatic , viral , bacterial ( include upper respiratory infection ) fungal ( noncutaneous ) infection within 1 week prior admission clinical unit ( day 1 ) . Subject clinically significant abnormality physical examination , ECG clinical study protocoldefined clinical laboratory test screen day 1 . Subject mean pulse &lt; 50 &gt; 90 bpm ; mean systolic BP &gt; 140 mmHg ; mean diastolic BP &gt; 90 mmHg ( vital sign measurement take triplicate subject rest supine position 5 minute ; pulse measure automatically ) admission clinical unit ( day 1 ) . If mean BP exceed limit , 1 additional triplicate take . Subject mean correct QT interval use Fridericia 's formula ( QTcF ) &gt; 430 m ( male subject ) &gt; 450 m ( female subject ) screening . If mean QTcF exceed limit , 1 additional triplicate ECG take day 1 . Subject use prescribe nonprescribed drug ( include Salagen tablet pilocarpinecontaining eye drop month prior first study drug administration / vitamin , natural herbal remedy [ e.g. , St. John 's wort ] 2 week prior first study drug administration ) except occasional use paracetamol ( 2 g/day ) except use contraceptive hormone replacement therapy . Subject history smoking within 1 month prior first study drug administration ( day 1 ) . Subject history drinking &gt; 21 unit alcohol/week male subject &gt; 14 unit alcohol/week female subject ( 1 unit = 10 g pure alcohol = 250 mL beer [ 5 % ] 35 mL spirit [ 35 % ] 100 mL wine [ 12 % ] ) within 3 month prior admission clinical unit ( day 1 ) . Subject consume grapefruit Seville oranges grapefruit / Seville orangecontaining product within 72 hour prior admission clinical unit ( day 1 ) . Subject use inducer metabolism ( e.g. , barbiturate , rifampin ) within 1 month prior admission clinical unit ( day 1 ) . Subject use drug abuse within 3 month prior admission clinical unit ( day 1 ) . Subject significant blood loss , donate 1 unit ( 500 mL ) blood , receive transfusion blood blood product within 60 day donate plasma within 7 day prior admission clinical unit ( day 1 ) . Subject positive serology test hepatitis B surface antigen , hepatitis A virus antibody ( immunoglobulin M ) , hepatitis C virus antibody , antibody human immunodeficiency virus type 1 ( HIV1 ) and/or type 2 ( HIV2 ) screening . Subject participate clinical study treat investigational drug within 28 day prior screen . Subject employee Astellas Group Contract Research Organization ( CRO ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Pilocarpine</keyword>
</DOC>